Diagnosis and Drug Treatment of Alzheimer's Disease in China is Low and Will Remain Low Th... ( WALTHAM Mass. Dec. 3 /- Decision Reso...)

Diagnosis and Drug Treatment of Alzheimer's Disease in China is Low and Will Remain Low Through 2012

Date:12/3/2008

WALTHAM, Mass., Dec. 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the diagnosis and drug treatment of Alzheimer's disease in China is extremely low and will remain low through 2012, particularly in rural regions. Although rural cases of Alzheimer's disease will account for approximately 70 percent of the prevalent Alzheimer's disease population in China in 2012, less than 10 percent of cases will be diagnosed and even fewer will be treated with approved Alzheimer's disease products.

"Public and professional awareness and prioritization of Alzheimer's disease in China is poor," stated Jonathan Searles, analyst at Decision Resources. "Patients and caregivers -- and even physicians -- across the nation consider Alzheimer's a natural part of aging and largely untreatable. Coupled with the severe stigma attached to the disease and the high cost of approved therapies, market opportunities for Alzheimer's disease therapies in China will remain constrained."

The new Emerging Markets report entitled Alzheimer's Disease in China also finds that the Chinese Alzheimer's disease drug market will continue to stay untapped and underserved despite growing use of approved therapies. Huperzine A (Chinese brands) and donepezil (Eisai's Aricept, Chinese brands) dominated the treatment of Alzheimer's disease, together capturing nearly 80 percent market share in 2007.

In spite of the continued dominance of costly therapies, including growing use of memantine (Lundbeck's Ebixa) -- the most recently-launched and most expensive Alzheimer's disease therapy in China -- the Chinese Alzheimer's drug market is expected to reach a mere $33 million in 2012, due chiefly to the limited pool of treated patients and competition from older, entrenched medicines.

"Ultimately, patients and physicians in China -- espe
'/>"/>

1

GOOD

Page: 1 2 3
Related medicine news :

1. Consumers Uncertain About Their Medical Diagnosis & Treatment
2. SpectraScience Awarded European Patent for Its Optical Biopsy System for Tissue Diagnosis
3. Med school discovery could lead to better cancer diagnosis, drugs
4. Future Looks Bright For Non-Invasive Diagnosis Of Skin Cancer; Study Shows Novel Light Device Detects Cancerous Lesions From Normal Tissue
5. 3 clinical features identified to avoid misdiagnosis of TIAs
6. Wisconsin Health System Installs Computer System for Diagnosis Support
7. More People Living Longer After Cancer Diagnosis
8. Head Injury in Young Kids May Predict ADHD Diagnosis
9. Study reports Double Balloon Endoscopy useful for diagnosis and treatment of obscure GI bleeding
10. Pathwork Tissue of Origin Test Shows Potential to Aid in the Diagnosis of Cancer of Unknown Primary
11. Other Health Problems Can Delay MS Diagnosis

Post Your Comments:

Diagnosis and Drug Treatment of Alzheimer's Disease in China is Low and Will Remain Low Th...( WALTHAM Mass. Dec. 3 /- Decision Reso...),Health